Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer

Fig. 4

Sequential therapy of FAP-targeted and CLDN18.2-targeted cells dramatically improved antitumor efficacy against CLDN18.2-positive tumor-bearing mice. a-d In vivo experimental design. C57BL/6 mice were injected s.c. with PANC02-A2 cells and allowed to establish for 10 days. Mice were assigned to four experimental groups. The first and second CAR-T cells were injected on day 10 and day 18, respectively (i.v.; n = 5 mice per group). b The tumor growth inhibition of each treatment group. c The volume of tumors of each treatment group. d The body weight of mice of each treatment group. e-h In vivo experimental design. C57BL/6 mice were injected s.c. with KPC1199 cells and allowed to establish for 12 days. Mice were assigned to four experimental groups. The first and second CAR-T cells were injected on day 12 and day 19, respectively (i.v.; n = 5 mice per group). f The tumor growth inhibition of each treatment group. g The volume of tumors of each treatment group. h The body weight of mice of each treatment group. All data are presented as the mean ± SEM of triplicate experiments. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page